Swiss biotech 4bases and the University of Florence began clinical pilot studies validating nanopore sequencing for copy‑number variant detection in two Italian hospitals using the KaryoSolver workflow. The pilot aims to compare real‑time nanopore cytogenetics with traditional array‑CGH, touting a potential turnaround time of roughly 24 hours versus three days for arrays and increased multiplexing on PromethION flow cells. If pilots validate performance and workflow robustness, 4bases plans to commercialize KaryoSolver in Q2. The projects highlight nanopore sequencing’s transition from research proofs to clinical diagnostics and could accelerate adoption where faster CNV detection and lab throughput are priorities.